全文获取类型
收费全文 | 436篇 |
免费 | 33篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 17篇 |
妇产科学 | 6篇 |
基础医学 | 72篇 |
口腔科学 | 14篇 |
临床医学 | 47篇 |
内科学 | 96篇 |
皮肤病学 | 8篇 |
神经病学 | 15篇 |
特种医学 | 30篇 |
外科学 | 29篇 |
综合类 | 14篇 |
预防医学 | 87篇 |
药学 | 21篇 |
中国医学 | 2篇 |
肿瘤学 | 18篇 |
出版年
2023年 | 3篇 |
2022年 | 18篇 |
2021年 | 30篇 |
2020年 | 7篇 |
2019年 | 15篇 |
2018年 | 9篇 |
2017年 | 10篇 |
2016年 | 18篇 |
2015年 | 15篇 |
2014年 | 20篇 |
2013年 | 22篇 |
2012年 | 28篇 |
2011年 | 37篇 |
2010年 | 17篇 |
2009年 | 20篇 |
2008年 | 26篇 |
2007年 | 16篇 |
2006年 | 20篇 |
2005年 | 8篇 |
2004年 | 10篇 |
2003年 | 18篇 |
2002年 | 9篇 |
2001年 | 16篇 |
2000年 | 6篇 |
1999年 | 6篇 |
1998年 | 7篇 |
1997年 | 10篇 |
1996年 | 4篇 |
1995年 | 4篇 |
1994年 | 6篇 |
1993年 | 4篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1989年 | 6篇 |
1988年 | 7篇 |
1987年 | 2篇 |
1986年 | 4篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1977年 | 1篇 |
1976年 | 2篇 |
1975年 | 2篇 |
排序方式: 共有477条查询结果,搜索用时 484 毫秒
1.
A retrospective study was performed to compare intravenous lorazepam and intravenous diazepam in the treatment of status epilepticus. Forty-five episodes of status epilepticus in children between the ages of 2 weeks and 18 years were reviewed. Lorazepam and diazepam proved similar in efficacy of seizure control and incidence of adverse effects. The dose of lorazepam required to control status epilepticus ranged from 0.03 to 0.22 mg/kg with a mean of 0.11 mg/kg (S.D. = 0.05 mg/kg). Among children treated with lorazepam, only children younger than 2 years of age had respiratory depression which required intubation. 相似文献
2.
Huisman JA; Paulussen RJ; Geurts TB; Odink J; Rekers H 《Human reproduction (Oxford, England)》1997,12(1):34-38
The objective was to demonstrate bioequivalence between s.c. and i.m.
administration of Humegon (FSH/LH ratio 1:1) and Normegon (FSH/LH ratio
3:1). In two randomized, single-centre, cross-over studies, 18 healthy
volunteers on each formulation were assigned to one of the two
administration sequences. Subjects were given single doses of one of the
above gonadotrophins after endogenous gonadotrophin production had first
been suppressed using high-dose oral contraceptive. Subsequently, rate
(Cmax, tmax) and extent (AUC) of absorption of follicle stimulating hormone
(FSH) and luteinizing hormone (LH) were determined for 14 days. For Cmax
and AUC, analysis of variance (ANOVA) was performed on log-transformed data
and for tmax ANOVA was performed on ranks. Intramuscular and s.c.
injections of Humegon were bioequivalent with respect to the main
pharmacokinetic parameters, being AUC and Cmax of FSH absorption.
Intramuscular and s.c. injections of Normegon were bioequivalent with
respect to the AUC of FSH and not bioequivalent with respect to the Cmax of
FSH. For tmax of FSH as well as for most LH variables of both preparations,
bioequivalence could not be proven due to the high intra- and
interindividual variability and/or concentrations being close to the
detection limit. Thus, the main pharmacokinetic FSH variables after i.m.
and s.c. administration of Humegon and Normegon were bioequivalent.
相似文献
3.
4.
Nguyen Minh Hai Nguyen Dang Dung Dinh Cong Pho Vu Tung Son Vu Ngoc Hoan Phan Tan Dan Bui Dang The Anh La Huong Giang Pham Ngoc Hung 《Vaccine》2021,39(7):1140-1147
BackgroundROTAVAC® is derived from human 116E rotavirus (RV) neonatal strain. In this study, we evaluated the immunogenicity, safety and reactogenicity of ROTAVAC® in Vietnam.MethodWe conducted a phase IV clinical trial in healthy infants aged 6–8 weeks using the complete regimen of ROTAVAC® with three doses. Serum anti-RV IgA was measured by enzyme-linked immunosorbent assay to assess the geometric mean concentration in infants who received the complete regimen of the vaccine.ResultsA total of 360 participants were enrolled in this clinical trial. The mean age ± standard deviation at enrollment was 6.9 ± 0.6 weeks. The anti-RV IgA titer was 4.01 ± 3.74 mg/ml pre-vaccination and substantially increased to 29.27 ± 80.64 mg/ml post-vaccination. The value of logIgA significantly increased (p = 0.003) from 0.28 ± 0.79 to 1.03 ± 0.54. The proportion of participants with equal to and greater than 3-fold and 4-fold shifts in pre- to post-vaccination antibody titer (IgA) were 55.4% and 48.3%, respectively. No adverse events or serious adverse events were recorded immediately within 30 min after the administration of each dose. The most common adverse events within 14 days after each visit were fever, unusual crying and irritability. Other adverse events occurred at a low rate, and no case of intussusception was noted.ConclusionsThe complete regimen of ROTAVAC® demonstrated an immunological response with clinically acceptable safety profile. Post-completion of this study, ROTAVAC® is now a WHO-prequalified vaccine and available in Vietnam. 相似文献
5.
Weinstein A Schwid SR Schiffer RB McDermott MP Giang DW Goodman AD Schwid SI 《Archives of neurology》1999,56(3):319-324
BACKGROUND: Glatiramer acetate (Copaxone) therapy reduces clinical disease activity in relapsing-remitting multiple sclerosis (MS). OBJECTIVE: To study the effect of glatiramer therapy on neuropsychologic function as part of a randomized, placebo-controlled, multicenter trial. METHODS: Two hundred forty-eight patients with relapsing-remitting MS and mild to moderate disability (Expanded Disability Status Scale score, <5.0) were tested before and 12 and 24 months after randomization to administration of glatiramer acetate, 20 mg/d, or matching placebo. Neuropsychologic tests examined 5 cognitive domains most often disrupted in patients with MS: sustained attention, perceptual processing, verbal and visuospatial memory, and semantic retrieval. RESULTS: Baseline neuropsychologic test performance was similar in both treatment groups and was within normal range, except for impaired semantic retrieval. Mean neuropsychologic test scores were higher at 12 and 24 months than at baseline, and no differences were detected between treatment groups over time. No significant interactions were detected between treatment and either time or baseline impairment. CONCLUSIONS: Our 2-year longitudinal study showed no effect of glatiramer therapy on cognitive function in relapsing-remitting MS. Although it is possible that glatiramer therapy has no effect on cognitive function, the lack of measurable decline in cognitive function in both patient groups for 2 years limits the opportunity for glatiramer to demonstrate a therapeutic effect by minimizing such decline. Emerging treatments for MS should continue to be examined for their effect on cognitive impairment because it can be a critical determinant of disability. A greater understanding of the natural history of cognitive decline in MS is essential for a rational design of these drug trials. 相似文献
6.
传染性肺结核患者家庭中儿童结核感染发病及预防的研究 总被引:3,自引:1,他引:3
马丽萍 《中国实用儿科杂志》2003,18(5):277-279
目的 分析传染性肺结核患者家庭中的儿童结核感染和发病情况 ,探讨预防儿童发病的有效方案。方法 对与传染性肺结核患者密切接触的儿童进行X线胸透和做结核菌素试验 ;对结核菌素强阳性者给予预防性治疗。结果 与传染性肺结核患者密切接触的儿童感染率为 88 2 %。规则预防治疗组、不规则预防治疗组和不接受预防治疗组的患病率分别为 :8 3%、4 7 6 %、5 8 8%。结论 与传染性肺结核患者密切接触的儿童属于高危人群 ,给予预防性治疗可减少发病。 相似文献
7.
8.
9.
Ha Ngoc Giang Kenji Kinashi Wataru Sakai Naoto Tsutsumi 《Macromolecular chemistry and physics.》2012,213(9):982-988
A new class of photorefractive (PR) composite based on a fully functionalized polymer with high phase‐stability is reported. The polymer containing non‐linear optical (NLO) chromophores and charge‐transporting carbazole moieties is synthesized by a polymer‐analogous reaction. The polymer is doped with plasticizer, NLO dye, and sensitizer to fabricate the PR composite. The NLO dye is the same as the NLO chromophore moiety in the polymer side chain. The PR performance of the composite is evaluated by degenerated four‐wave mixing and two‐beam coupling measurements. A diffraction efficiency of 30% at a relatively low applied electric field of 45 V μm?1 is achieved. Despite a high concentration of NLO dye, the composites show good stability for a long period without phase separation. 相似文献
10.